Drug intelligence / Profile preview

BFB759

Development stage: Phase 3
Lead developer: Bluefin Biomedicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BFB759 is a specially designed monoclonal antibody developed to treat moderate to severe atopic dermatitis. It acts by blocking multiple inflammation-causing substances believed to drive symptoms of atopic dermatitis, including redness, swelling, itching, and skin damage. The drug is being evaluated for safety and efficacy in adult patients whose disease is not adequately controlled by topical treatments. The primary study sponsor is Bluefin Biomedicine, and BFB759 is administered in a double-blind, placebo-controlled, parallel-arm, dose-ranging Phase 2 study[1][2][3][7].

Beyond the preview

Go deeper on BFB759.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BFB759.

Explore the full profile